01 Preference for Home-Based Oxygen Therapy The asbestosis treatment market analysis indicates preference for home-based oxygen therapy among patients with severe respiratory impairment. Portable oxygen concentrators support patient mobility and enable prescribed oxygen therapy outside hospitals. For example, Inogen's Rove 6 portable oxygen concentrator offers six pulse dose settings and up to 12 hours and 45 minutes of battery life.
02 Adoption of Pulmonary Telerehabilitation Pulmonary telerehabilitation is gaining importance in the management of chronic respiratory diseases, including conditions requiring long-term respiratory support. Remote exercise supervision and patient education improve access to rehabilitation services for individuals with limited mobility. The American Thoracic Society recommends offering patients with chronic respiratory diseases a choice between center-based rehabilitation and telerehabilitation.
01 Supply chain disruptions are expected to have a moderate impact on the asbestosis treatment market share, mainly due to shortages of oxygen concentrators, respiratory equipment, and medical components. The market is expected to experience a K-shaped recovery as established medical device manufacturers maintain stable supplies through diversified sourcing. The market is projected to grow at a CAGR of 5.80%. Supply chain constraints could reduce short-term growth by 1.20 percentage points to 4.60%. Improved equipment availability and stable manufacturing operations are expected to support recovery toward 5.80%.
01 The asbestosis treatment market forecasts investment activity directed toward respiratory support technologies and pulmonary fibrosis research, supporting oxygen delivery innovation and the development of treatments for fibrotic lung diseases.
02 Key Investment and Funding Activities in Asbestosis Treatment Market, 2025–2026 Company Value (USD) Details Celea Therapeutics USD 180 Million In July 2026, Celea Therapeutics announced financing to advance Phase 3 development of deupirfenidone for idiopathic pulmonary fibrosis. University of Iowa USD 2.55 Million In August 2025, the University of Iowa announced NIH funding for the development of a portable oxygen concentrator using electrochemical technology.
01 Long Disease Latency and Need for Long-Term Respiratory Support Drive Market The long latency period of asbestosis is sustaining demand for respiratory treatment among previously exposed workers. Symptoms often develop 20–40 years after asbestos exposure, creating treatment needs decades after occupational contact. The World Health Organization estimates that occupational asbestos exposure causes more than 200,000 deaths globally each year across asbestos related diseases. The continuing disease burden supports demand for oxygen therapy and long-term pulmonary care.The progressive nature of asbestosis increases dependence on continuous medical care as lung function deteriorates. Patients with advanced disease may require supplemental oxygen to manage breathing difficulties. Regular pulmonary function assessments and respiratory monitoring also remain essential throughout treatment. The absence of curative treatment creates sustained demand for supportive care services and oxygen delivery equipment, particularly among patients experiencing severe respiratory impairment.
01 Absence of Curative Therapies and Limited Access to Specialized Pulmonary Rehabilitation Restrain Market Expansion The absence of disease-reversing treatment remains a major restraint in the asbestosis treatment market. Existing therapies primarily manage breathing difficulties without removing established lung scarring. Oxygen therapy and pulmonary rehabilitation provide supportive benefits but cannot reverse asbestos-related fibrosis. The limited availability of specialized pulmonary rehabilitation services restricts treatment access for asbestosis patients. Rehabilitation requires trained respiratory professionals and structured exercise supervision, which can be difficult to access outside major healthcare centers. Repeated hospital visits also create challenges for patients with reduced mobility.
01 AI-Assisted Lung Imaging and Development of Targeted Anti-Fibrotic Therapies Creates Growth Opportunities Integration of artificial intelligence into lung imaging presents growth opportunities for the asbestosis treatment market. AI-assisted CT analysis helps identify asbestos-related lung fibrosis and supports accurate disease assessment. These capabilities create opportunities for diagnostic technology providers and specialized pulmonary care centers.Development of targeted anti-fibrotic therapies presents opportunities for the asbestosis treatment market. Research into macrophage activity and cellular stress mechanisms could support treatments that slow asbestos-induced lung fibrosis. The U.S. National Institutes of Health is funding research into endoplasmic reticulum stress and its role in asbestos-related disease progression through May 2029. These developments create opportunities for disease-specific drug research, although effective targeted therapies remain investigational.